It was a pleasure to meet with Prof. Xenofon Baraliakos (Ruhr-University Bochum, Herne, Germany) to talk around his presentation on ‘Secukinumab in patients with psoriatic arthritis and axial manifestations: Predictors of response from the double-blind, randomised, phase 3b MAXIMISE trial.‘ (POS0930), which was presented at the European Congress of Rheumatology 2021, 2-5 June 2021.
Questions
- How is axial psoriatic arthritis currently defined and what are the challenges in its treatment? (0:27)
- What did the MAXIMISE study aim to add to our current knowledge of secukinumab in psoriatic arthritis? (1:41)
- Could you give us a brief overview of the study design? (2:51)
- What were the efficacy and safety of the two doses of secukinumab? (3:48)
- How will these findings impact clinical practice? (4:58)
Disclosures: Xenofon Baraliakos has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of EULAR 2021 (Virtual).
